

Prenatal Akinesia/Arthrogryposis Panel Sequence Analysis and Exon-Level Deletion/Duplication Testing

Panel Gene List: *ACTA1, CHRNA1, CHRND, CHRNE, CHRNG, CNTN1, CNTNAP1, DOK7, ECEL1, FKRP**, *GBE1, GLE1, KLHL40, LMOD3, MAGEL2, MUSK, MYBPC1, MYH3, PIEZO2, PLEC, RAPSN, RIPK4, TNNI2***, *TNNT3, TPM2, ZC4H2, ZMPSTE24*

*Sequence analysis only for *FKRP*

** Only whole gene deletions and duplications may be detected for *TNNI2*

Clinical Features:

Arthrogryposis, also known as arthrogryposis multiplex congenita (AMC), describes the presence of multiple non-progressive congenital joint contractures in at least two different areas of the body, leading to restricted movement of the affected joints.^{1,2} It generally results from fetal akinesia and has been noted as a clinical finding in more than 400 disorders. Fetal akinesia presents prenatally as abnormal joint positioning and/or lack of fetal movement on ultrasound.^{3,4} The most common manifestations include talipes equinovarus (club foot) and flexion deformities of the wrists, however involvement of the jaw, neck, or spine may be observed.¹ Other ultrasound findings include, craniofacial anomalies (micrognathia, retrognathia, cleft palate), polyhydramnios, cerebral ventriculomegaly, intrauterine growth retardation (IUGR), increased nuchal translucency, cystic hygroma, and fetal hydrops.³⁻⁵ Although fetal akinesia can be observed by ultrasound as early as 12 weeks' gestation, most cases are diagnosed during the second or third trimesters of pregnancy by ultrasound or maternal recognition of reduced fetal mobility.⁵ The use of 4D ultrasound can improve identification of reduced fetal movement at an earlier time point.⁶ Fetal akinesia and arthrogryposis can be caused by a variety of primary defects including disorders of the central or peripheral nervous systems, neuromuscular junction, musculature, connective tissue, or metabolic pathways.^{1,7} Central nervous system and neuromuscular junction diseases are the most common cause of fetal akinesia/severe arthrogryposis, which are associated with several prenatal or neonatal lethal conditions.⁸ Due to genetic heterogeneity and overlapping phenotypes, the specific diagnosis cannot be determined accurately with imaging alone. When available, genetic testing can aid in determining the precise diagnosis after the differential has been established by imaging.⁹

Genetics:

Fetal akinesia and arthrogryposis can be genetic or environmental in nature. Genetic forms of these disorders are inherited in an autosomal dominant, autosomal recessive, or X-linked manner, or they may be the result of a *de novo* variant. Pathogenic variants have been identified in genes that function in the central or peripheral nervous system, neuromuscular junctions, skeletal muscle, connective tissue, or skin.^{1,8}

Test Methods:

Using genomic DNA extracted from the submitted specimen, the complete coding regions and splice site junctions of the genes tested are enriched using a proprietary targeted capture system developed by GeneDx for next-generation sequencing with CNV calling (NGS-CNV). The enriched targets are simultaneously sequenced with paired-end reads on an Illumina platform. Bi-directional sequence reads are assembled and aligned to reference sequences based on NCBI RefSeq transcripts and human genome build GRCh37/UCSC hg19. After gene specific filtering, data are analyzed to identify sequence variants and most deletions and duplications involving coding exons; however, technical limitations and inherent sequence properties effectively reduce this resolution for some genes. Alternative sequencing or copy number detection methods are used to analyze or confirm regions with inadequate sequence or copy number data by NGS. Reportable variants include pathogenic variants, likely pathogenic variants and variants of uncertain significance. Likely benign and benign variants, if present, are not routinely reported but are available upon request.

The technical sensitivity of sequencing is estimated to be >99% at detecting single nucleotide events. It will not reliably detect deletions greater than 20 base pairs, insertions or rearrangements greater than 10 base pairs, or low-level mosaicism. The copy number assessment methods used with this test cannot reliably detect copy number variants of less than 500 base pairs or mosaicism and cannot identify balanced chromosome aberrations. Assessment of exon-level copy number events is dependent on the inherent sequence properties of the targeted regions, including shared homology and exon size. Gene specific exclusions for exon-level deletion/duplication testing for this panel are: FKR1 gene, no copy number testing, TNNI2 gene only whole gene deletions or duplications may be detected.

Additionally, genotype analysis of maternal and fetal DNA for several polymorphic markers to test for maternal cell contamination is performed. Therefore, in all prenatal cases, a maternal sample should accompany the fetal sample.

Clinical Sensitivity:

The clinical sensitivity of sequencing and deletion/duplication analysis of the genes included in this panel depends in part on the patient's clinical phenotype. Specific information about the diagnostic yield for each gene in selected populations is summarized in the table below.

Diagnostic Yield of Prenatal Akinesia/Arthrogryposis Panel Genes in Selected Populations

Gene	Inheritance	Disease Associations	Diagnostic Yield in Selected Postnatal Population(s)
ACTA1	AD/AR	Congenital fiber-type disproportion myopathy; Nemaline myopathy(NM)	15-25% of NM; ¹⁰ Rare for AMC ^{11,12}
CHRNA1	AD/AR	Congenital myasthenic syndrome(CMS); LMPS	<1% for CMS; ¹³ ~3% for FADS ¹⁴
CHRND	AD/AR	CMS; LMPS	<1% for CMS; ¹³ ~3% for FADS ¹⁴
CHRNE	AD/AR	CMS	49% for CMS; ¹³ Rare for AMC ¹¹
CHRNA1	AR	LMPS; Escobar syndrome (EVMPS)	~27% of EVMPS; ¹⁵ 5-8% patients with LMPS/FADS; ^{14,15} 7-10% for AMC ^{16,17}
CNTN1	AR	Compton-North congenital myopathy	Rare for AMC ¹¹
CNTNAP1	AR	Congenital hypomyelinating neuropathy;LCCS 7	~13% for AMC ¹⁷
DOK7	AR	DOK7-related CMS; FADS	10-21% for CMS; ^{18,19} ~7% for lethal MPS/FADS without <i>CHRNA1</i> , <i>CHRNB1</i> , <i>CHRND</i> , or <i>RAPSN</i> ²⁰
ECEL1	AR	Distal arthrogryposis type 5D (DA5D)	~70% DA5D; ²¹ ~3-6% for AMC ^{16,17}
FKRP	AR	Walker-Warburg syndrome; congenital muscular dystrophy (CMD) with/without intellectual disability and microcephaly; Limb-girdle muscular dystrophy (LGMD) type 2	~6% of AR LGMD; ²² ~9% of the alpha-dystroglycanopathies; ²³ rare for AMC ¹¹
GBE1	AR	Glycogen storage disease IV	3% of glycogen storage disease; ²⁴ ~2% for AMC ¹¹
GLE1	AR	LCSS 1/Lethal arthrogryposis with anterior horn cell disease	Unknown ²⁵
KLHL40	AR	NM	~20% of severe NM; ²⁶ rare for AMC ¹¹
LMOD3	AR	Nemaline myopathy	Unknown ^{7,27}
MAGEL2	AD	Schaaf-Yang syndrome	Unknown ²⁸
MUSK	AR	CMS;FADS	Rare for CMS; ¹⁸ unknown for AMC, founder mutation (p.Ile575Thr) causing FADS among the Dutch ²⁹
MYBPC1	AD/AR	DA type 1B(AD);LCCS4	~13% for DA1 family ³⁰
MYH3	AD	DA1;DA2A/FSS,DA2B/SHS;DA8	~8% for DA1; ³¹ ~90% for DA2A/FSS; ^{32,33} 11-32% for DA2B/SHS; ^{31,32} rare for DA8; ³⁴ ~3% for AMC ¹⁷
PIEZO2	AD/AR	DA3/Gordon syndrome & DA5	~83% for DA3 and ~82% for DA5 ³⁵

Gene	Inheritance	Disease Associations	Diagnostic Yield in Selected Postnatal Population(s)
PLEC	AD/AR	Epidermolysis bullosa simplex with muscular dystrophy (EBS-MD); Limb-girdle muscular dystrophy 2Q (LGMD2Q)	Rare ³⁶
RAPSN	AR	CMS;FADS	~1.5% for FADS; ¹⁴ ~3% for AMC ¹⁷
RIPK4	AR	Lethal popliteal pterygium syndrome/Bartsocas-Papas type	Rare ^{11,37}
TNNI2	AD	DA1&2B	~10% of DA2B and 6% for DA1 ³¹
TNNT3	AD	DA1&2B	~8% for DA1 and ~7% for DA2B; ³¹ ~3% for AMC ¹⁷
TPM2	AD	DA 1&2B; NM	~6% for DA1 and ~10% for DA2B; ³¹ ~2% for AMC ¹¹
ZC4H2	XLR	Wieacker-Wolff syndrome	Rare ³⁸
ZMPSTE24	AR	Mandibuloacral dysplasia with type B lipodystrophy; Lethal restrictive dermopathy	~75% for restrictive dermopathy ³⁹

References:

1. Hall (2014) Eur J Med Genet. 57(8):464-72 (PMID:24704792) 2. Kowalczyk et al. (2014) Arch Med Sci.12(1):10-24 (PMID:26925114) 3. Kalampokas et al. (2012) ISRN Obstet Gynecol. 2012:264918 (PMID: 23050160) 4. Dimitrakaki et al (2011) J Matern Fetal Neonatal Med. 24(1):32-6 (PMID:20569162) 5. Chen (2012) Taiwan J Obstet Gynecol. 51(1):12-7 (PMID: 22482962) 6. Pooch et al (2012) J Matern Fetal Neonatal Med. 25(5):433-55 (PMID: 22082334) 7. Beecroft et al. (2018) J Med Genet. 55(8):505-514 (PMID:29959180) 8. Bamshad et al. (2009) J Bone Joint Surg Am.91(Suppl 4):40-6 (PMID:19571066) 9. Filges et al. (2013) Prenat Diagn. 33(1):61-74 (PMID: 23296716) 10. North et al. 2002 Jun 19 [Updated 2015 Jun 11]. In: Adam MP et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK1288/> 11. Bayram et al. (2016) J Clin Invest.126(2):762-78 (PMID: 26752647) 12. Ahmed et al. (2018) Am. J. Med. Genet. A 176 (2):359-367 (PMID: 29274205) 13. Abicht et al., (2012) Human Mutation 33 (10): 1474-1484 (PMID: 22678886) 14. Michalk et al. (2008) Am J Hum Genet. 82(2):464-76 (PMID: 18252226) 15. Vogt et al. (2012) J. Med. Genet. 49 (1):21-6 (PMID: 22167768) 16. Pehlivan et al. (2019) Am. J. Hum. Genet. 105(1):132-150 (PMID: 31230720) 17. Laquériere et al. (2014) Hum Mol Genet.23(9):2279-89 (PMID: 24319099) 18. Engel et al., (2012) Neuromuscular Disorders 22 (2): 99-111 (PMID: 22104196) 19. Abicht et al., (1999) Neurology 53 (7): 1564-1569 (PMID: 10534268) 20. Vogt et al. (2009) J Med Genet. 46(5):338-40 (PMID:19261599) 21. McMillin et al. (2013) Am J Hum Genet.92(1):150-6 (PMID:23261301) 22. Pegoraro et al 2002 Jun 8 [Updated 2012 Aug 30]. In: Adam MP et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. Available from: <http://www.ncbi.nlm.nih.gov/books/NBK1408/> 23. Wicklund, M.P. (2013). Continuum (Minneapolis) 19, 1535-1570 (PMID:24305447) 24. Magoulas et al. 2013 Jan 3. In: Adam MP, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK115333/> 25. Said et al. (2017) Am. J. Med. Genet. A 173 (11):3098-3103 (PMID: 28884921) 26. Ravenscroft et al. (2013) Am J Hum Genet. 93(1):6-18 (PMID: 23746549) (for KLHL40 gene) 27. Yuen et al. (2014) J. Clin. Invest. 124 (11):4693-708 (PMID: 25250574) 28. Mejlachowicz et al. (2015) Am. J. Hum. Genet. 97 (4):616-20 (PMID: 26365340) 29. Tan-Sindhunata et al. 2015 Eur J Hum Genet. 23(9):1151-7(PMID:25537362) 30. Gurnett et al. (2010) Hum Mol Genet.19(7):1165-73 (PMID: 20045868) 31. Beck et al. (2013) Am J Med Genet A. 161A(3):550-5 (PMID:23401156) 32. Toydemir et al. (2006) Nat Genet. 38(5):561-5 (PMID:16642020) 33. Beck et al. (2014) Am J Med Genet A.164A, 2808–281 (PMID:25256237) 34. Chong et al. (2015a) Am J Hum Genet. 96(5):841-9 (PMID:25957469) 35. McMillin et al. (2014) Am J Hum Genet. 94(5):734-44 (PMID: 24726473) 36. Charlesworth et al. (2003) The Journal Of Investigative Dermatology 121 (6):1344-8 (PMID: 14675180) 37. Kalay et al. (2012) American Journal Of Human Genetics 90 (1):76-85 (PMID: 22197489) 38. Hirata et al. (2013) American Journal Of Human Genetics 92 (5):681-95 (PMID: 23623388) 39. Navarro et al. (2004) Hum Mol Genet. 13(20):2493-503 (PMID: 15317753)